Herantis Pharma Plc – Press release
- Indivi’s digital biomarker platform is designed to enable earlier and more sensitive detection of treatment-related changes
- Improved sensitivity and reduced variability may support more efficient clinical studies, including shorter study duration and smaller patient cohorts
Espoo, Finland, May 19, 2026: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces a collaboration with Indivi, a Basel-based TechBio company focused on advancing precision medicine in neuroscience drug development, to integrate Indivi’s digital biomarker platform into Herantis’ upcoming Phase 2 proof-of-concept study of HER-096 in people living with Parkinson’s disease.
Indivi’s platform provides functional digital biomarkers derived from smartphone-based assessments of motor and cognitive function, enabling sensitive high-frequency multi-domain disease phenotyping that may support earlier detection of treatment-related changes compared to conventional clinical assessments.
Under the collaboration, Herantis Pharma will incorporate Indivi’s platform alongside conventional clinical assessments in its upcoming double-blind, placebo-controlled, randomized Phase 2 study of HER-096, with the aim of detecting early changes in motor and cognitive function following treatment.
Preparations for the proof-of-concept study are on track and are being further optimized for the integration of Indivi’s digital biomarker platform. Herantis expects to provide additional updates on the Phase 2 trial following completion of the study design.
Antti Vuolanto, CEO of Herantis Pharma, said: “Digital biomarkers have the potential to significantly improve the sensitivity and efficiency of clinical development in Parkinson’s disease. Following an evaluation of available digital health technology solutions, we selected Indivi based on the strength of its scientific capabilities, platform performance, and experience supporting neuroscience clinical studies with leading biotechnology and pharmaceutical companies. We believe the ability to sensitively detect early treatment-related changes in motor and cognitive function may become an important advantage in evaluating the therapeutic potential of HER-096. We are very pleased to collaborate with Indivi and look forward to working together to further strengthen the clinical evaluation of HER-096.”
Shibeshih Mitiku Belachew, Chief Medical Officer of Indivi, said: “We are excited to collaborate with Herantis on HER-096 program, a promising and differentiated investigational therapy for disease modification in people living with Parkinson’s disease. The mechanism of action of HER-096 is highly compelling, and we believe our digital biomarker platform is particularly well suited to capturing early symptomatic signals and treatment-related changes with greater sensitivity and precision than conventional assessments.”
-End-
For more information, please contact:
Herantis Pharma:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com
Sarah Elton-Farr, Stephanie Cuthbert, Phillip Marriage
Tel: +44 20 3709 5700
Email: herantispharma@icrhealthcare.com
Certified Advisor:
UB Corporate Finance Ltd
Tel.: +358 9 25 380 225
E-mail: ubcf@unitedbankers.fi
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients.
Herantis is listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com
About HER-096
Herantis Pharma is developing HER-096, a first-in-class drug candidate with the potential to stop the progression of Parkinson’s disease, repair striatal damage and significantly improve both an individual’s symptoms and quality of life.
HER-096 is a small peptide molecule based on the active site of and designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF), a protein known to promote neuronal cell survival and functional recovery.
HER-096’s multimodal mechanism of action targets key drivers of neurodegeneration in PD by modulation of the Unfolded Protein Response (UPR) pathway, reducing aggregation of the neurotoxic protein α-synuclein, and modulation of neuroinflammation. Combined with its demonstrated brain penetration, this enables HER-096 to protect dopamine neurons from further degeneration and supports their functional restoration.
About Indivi
Indivi is a Basel-based TechBio company advancing precision medicine in neuroscience drug development. Neurodegenerative diseases have historically low success rates, with high attrition during the transition from first-in-human to proof-of-concept studies, where conventional endpoints often lack sensitivity to detect early therapeutic effects. Indivi’s multi-modal deep phenotyping platform integrates digital measurement tools, including motor assessments and CoGames - a proprietary battery of gamified, user-adaptive cognitive assessments. These tools increase the signal-to-noise ratio of clinical endpoints, enabling more precise and sensitive detection of treatment effects.
Forward-looking statements
This release includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis’ future financial position and results of operations, the Company’s strategy, objectives, future developments in the markets in which the Company participates or is seeking to participate or anticipated regulatory changes in the markets in which the Company operates or intends to operate. In some cases, forward-looking statements can be identified by terminology such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “plan,” “potential,” “predict,” “projected,” “should” or “will” or the negative of such terms or other comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance and are based on numerous assumptions. The Company’s actual results of operations, including the Company’s financial condition and liquidity and the development of the industry in which the Company operates, may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this company release. Factors, including risks and uncertainties that could cause these differences include, but are not limited to risks associated with implementation of Herantis’ strategy, risks and uncertainties associated with the development and/or approval of Herantis’ drug candidates, ongoing and future clinical trials and expected trial results, the ability to commercialize drug candidates, technology changes and new products in Herantis’ potential market and industry, Herantis’ freedom to operate in respect of the products it develops (which freedom may be limited, e.g., by competitors’ patents), the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. In addition, even if Herantis’ historical results of operations, including the Company’s financial condition and liquidity and the development of the industry in which the Company operates, are consistent with the forward-looking statements contained in this company release, those results or developments may not be indicative of results or developments in subsequent periods.
